European Commission Research & Innovation Initiatives and Programme Opportunities
Overview of all programmes
Filter by status

EU Mission on Cancer

Specific support for cancer projects in Horizon 2020’ and replace with: ‘One of five EU Missions, the Mission on Cancer together with the Europe’s Beating Cancer Plan aims to provide a better understanding of cancer, allow for earlier diagnosis and optimisation of treatment and improve cancer patients’ quality of life during and beyond their cancer treatment.

Read More

European Innovation Council (EIC) Accelerator

EIC Accelerator supports smaller actors in developing innovative solutions that would allow them to scale up. The focus is on innovations building on scientific discovery or technological breakthroughs (‘deep tech’) and where significant funding is needed over a long timeframe before returns can be generated.

Read More

European Innovation Council (EIC) Transition

EIC Transition supports the maturation and validation of novel technology in the lab and in relevant application well as the development of a business case and business model to commercialise this novel technology.

Read More

European Investment Bank (EIB)

The European Investment Bank (EIB) works closely with other EU institutions to foster European integration, promote the development of the EU and support EU policies in over 160 countries around the world.

Read More

European Partnership for Fostering a European Research Area for Health (ERA4Health)

The European Partnership for Fostering a European Research Area for Health (ERA4Health) is a partnership between 33 countries covering 17 of the 27 actual members of the European Union, 3 Third countries associated with Horizon Europe (Israel, Norway and Turkey) and 2 Third countries (Egypt and Taiwan). It aims to improve flexible joint programming with a specific focus on research funders. This partnership aims to include smaller EU research funders.

Read More

European Partnership for Pandemic Preparedness

The European Partnership on Pandemic Preparedness aims to improve the European Union’s (EU) preparedness to predict, prevent and respond to emerging infectious health threats by better coordinating funding for research and innovation at EU, national (and regional) levels. Proposed in February 2022, the Partnership is currently being negotiated, and expected to become fully operational within future Horizon Europe Work Programmes.

Read More

European Partnership on One-Health Anti-Microbial Resistance (OH AMR)

The One Health Antimicrobial Resistance (OH AMR) partnership aims to support the coordination and alignment of AMR research activities and funding in Europe and beyond. The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the World Health Organization (WHO) Global Action Plan on AMR, by reducing the threat of AMR and contribute to achieving the objectives of the Health Emergency Preparedness and Response Authority (HERA). Proposed in February 2022, the Partnership is currently being negotiated, and expected to become fully operational within future Horizon Europe Work Programmes.

Read More

European Partnership on Rare Diseases (RD)

The Rare Diseases partnership aims to enhance stakeholder collaboration on rare diseases to improve the life of patients by developing treatments and diagnostics. Proposed in February 2022, the Partnership is currently being negotiated, and expected to become fully operational within future Horizon Europe Work Programmes.

Read More

Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU)

The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union (EU) and the EDCTP Association, whose members are several European and African countries. It supports the development of new solutions for reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities to prepare and respond to re-emerging infectious diseases in this region and worldwide.

Read More

Innovative Health Initiative (IHI)

The Innovative Health Initiative Joint Undertaking (IHI JU) aims to foster innovation across the health industry, covering the entire cycle of healthcare, in close cooperation with industry players.
Under the 2024 work programme, two calls are open.

Read More

Research Infrastructures (RIs)

Research Infrastructures (RIs) aim to address global environmental, social and economic challenges by maximising science and technological contributions to meet societal needs whilst increasing the European Union’s (EU) competitiveness. RIs provide resources and services for the research communities to conduct research and foster innovation in their fields.  Examples of resources and services provided include, but are not limited to equipment or sets of instruments, knowledge-related facilities, archives or scientific data infrastructures, computing systems, and communication networks.

Read More

What type of funding are you looking for?

  • Grant:
    Grants are direct financial contributions from the European Union budget awarded by way of a donation to third-party beneficiaries (usually non-profit-making organisations) engaged in activities that serve EU policies.
  • Loan:
    Loans are measures of financial support provided on a complementary basis from the budget in order to address specific policy objectives of the European Union. Such instruments are implemented in partnership with public and private institutions such as banks, venture capitalists or angel investors.

What stage of development are you seeking R&I funding for?

  • Basic science: Basic science covers the various exploratory steps even prior to discovery
  • Discovery: Drug discovery aims to find potential disease-altering targets, such as a gene or a protein in humans. Prior to testing candidate compounds for safety
  • Preclinical development: Preclinical development concerns the testing of candidate compounds for safety in specific indications or disease conditions. Introduction of candidate compound in living biological systems (animals)
  • Phase 1 clinical trials: These are the first clinical trials on humans(usually 20-80 volunteers) testing the safety, side effects, best dose, and timing of a new treatment
  • Phase 21/2b clinical trials: This is the follow-up trial with roughly 100 to 500 patients to analyse efficacy and safety
  • Phase 3 clinical trials: These trials usually involve several hundreds to many thousands patients and tests the results of earlier clinical trials on larger populations to generate robust data on safety, efficacy and benefit-risk relationships of the medicine. Comparison to placebo and/or active comparator (best standard treatment)
  • Registration & launch: This concerns post-study, prior to launch, activities related to market launch. That can include, among others, marketing authorisation, regulatory activities, post-study communication or HTA
  • Introduction & delivery: This concerns all post-launch activities

What do you want to develop?

  • Treatment or vaccine:
    Refers to a drug or vaccine
  • Diagnostic or medical device:
    Refers to diagnostics and medical devices
  • Platform:
    Refers to a digital health platform or medical app
  • Knowledge:
    Refers to conducting research to help build our understanding on a topic
  • Standards:
    Refers to creating a benchmark for a specific issue

What type of organisation are you?

  • Small & medium-sized enterprises:
    <250 employees, annual revenue <EUR 50,000,000) or balance sheet < EUR43 million. This applies to individual firms only. If part of larger group, check the User Guide:
  • Large enterprises:
    >250 employees or annual revenue > EUR 50,000,000. Non-profit organisation (non-governmental organisations that are recognised with a non-profit status)
  • Non-profit organisations:
    Non-governmental organisations that are recognised with a non-profit status
  • Academic:
    Linked to a university or equivalent
  • Public:
    Local, regional, federal government representative

What stage of diagnostics development does your research aim to cover?

  • Development:
    Product development
  • Validation:
    Lab and clinical validation
  • Evaluation & Authorisation:
    Regulatory approvals
  • Access:

What stage of medicine or vaccine development does your research aim to cover?

  • Discovery and development:
    Identification of promising compounds for development and initial experiments to gather information
  • Preclinical research:
    Laboratory and animal testing to answer basic questions about safety
  • Phase 0 (clinical):
    Testing on limited number of subjects at subtherapeutic doses
  • Phase I (clinical):
    Testing on <100 healthy subjects with the disease/condition
  • Phase II (clinical):
    Testing on up to several hundred subjects with the disease/condition
  • Phase III (clinical):
    Testing on 300 to 3,000 volunteers with the disease/condition
  • Preregistration / Phase IV (clinical):
    Testing on several thousand volunteers with the disease/condition
  • Clinical (unspecified):
    Clinical phase unknown
  • Evaluation & Authorisation:
    Activities relating to marketing authorisation
  • Access:

Where are you based?

  • Africa : Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Congo (Democratic Republic of the), Congo (Republic of the), Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
  • America (non-US & Canada) : Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
  • Asia-Pacific : Afghanistan, Australia, Bangladesh, Bhutan, Burma, Brunei, Cambodia, China (including special administrative regions of Hong Kong and Macau), Cook Islands, Federated States of Micronesia, Fiji, India, Indonesia, Japan, Kiribati, Laos, Malaysia, Maldives, Marshall Islands, Mongolia, Nepal, New Caledonia, New Zealand, Niue, North Korea, Pakistan, Palau, Papua New Guinea, Philippines, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tonga, Tuvalu, Vanuatu, Vietnam
  • Europe (non-EU) : Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Iceland, Kosovo, Liechtenstein, Moldova, Monaco, Montenegro, North Macedonia, Norway, Russia, San Marino, Serbia, Switzerland, Turkey, Ukraine, United Kingdom
  • European Union (EU) : Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
  • Middle East : Cyprus, Lebanon, Syria, Iraq, Iran, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen
  • United States (US) & Canada : United States, Canada

What type of organisation are you?

  • Small and medium-sized enterprise (SME):
    Staff headcount 50 < and turnover ≤ EUR 10 m or balance sheet total ≤ EUR 10 m (small); Staff headcount 250 < and turnover ≤ EUR 50 m or balance sheet total ≤ EUR 43 m (medium)
  • Large enterprise:
    Staff headcount > 250
  • Non-profit organisation:
    Association, foundation, or equivalent
  • Academic:
    University, research institute, or equivalent
  • Individual:
    Private citizen
  • Public sector:
    Local, regional, federal government representative
  • Other:
    None of the above or uncertain